Biopharmaceutical News and Research

RSS
Schering-Plough announces licensing of Acadesine

Schering-Plough announces licensing of Acadesine

Cancer survivors share their advice in new book

Cancer survivors share their advice in new book

Roche and Alnylam form RNAi therapeutics alliance

Roche and Alnylam form RNAi therapeutics alliance

Experimental Alzheimer's drug begins clinical trials

Experimental Alzheimer's drug begins clinical trials

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Iloperidone shows promise for Akathisia

Iloperidone shows promise for Akathisia

Ulcerative colitis disruptive in relationships

Ulcerative colitis disruptive in relationships

Smokeless cannabis-vaporizing device may help those with HIV-related neuropathy

Smokeless cannabis-vaporizing device may help those with HIV-related neuropathy

New treatment for warts

New treatment for warts

Sigma-Aldrich acquires Molecular Medicine BioServices

Sigma-Aldrich acquires Molecular Medicine BioServices

New system for restoring damaged or lost knee cartilage tissue

New system for restoring damaged or lost knee cartilage tissue

Chitin compound causes allergic inflammation

Chitin compound causes allergic inflammation

Purdue molecule could lead to first drug treatment for Alzheimer's disease

Purdue molecule could lead to first drug treatment for Alzheimer's disease

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Use of computer-assisted drug design in drug discovery

Use of computer-assisted drug design in drug discovery

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Coley Pharmaceutical licenses VaxImmune to Merck

Coley Pharmaceutical licenses VaxImmune to Merck

BioMed Realty Trust embarks on $145 million expansion at Eastview

BioMed Realty Trust embarks on $145 million expansion at Eastview

Avista Capital acquires BioReliance from Invitrogen

Avista Capital acquires BioReliance from Invitrogen

Abbott agrees with WHO to expand access to lopinavir / ritonavir

Abbott agrees with WHO to expand access to lopinavir / ritonavir